Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, Hamid, Omid
Published in Journal of clinical oncology (01.12.2016)
Published in Journal of clinical oncology (01.12.2016)
Get full text
Journal Article
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer
Roach, Charlotte, Zhang, Nancy, Corigliano, Ellie, Jansson, Malinka, Toland, Grant, Ponto, Gary, Dolled-Filhart, Marisa, Emancipator, Kenneth, Stanforth, Dave, Kulangara, Karina
Published in Applied immunohistochemistry & molecular morphology (01.07.2016)
Published in Applied immunohistochemistry & molecular morphology (01.07.2016)
Get more information
Journal Article
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Dolled-Filhart, Marisa, Roach, Charlotte, Toland, Grant, Stanforth, Dave, Jansson, Malinka, Lubiniecki, Gregory M, Ponto, Gary, Emancipator, Kenneth
Published in Archives of pathology & laboratory medicine (1976) (01.11.2016)
Published in Archives of pathology & laboratory medicine (1976) (01.11.2016)
Get full text
Journal Article
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, Edward B, Rizvi, Naiyer A, Hui, Rina, Leighl, Natasha, Balmanoukian, Ani S, Eder, Joseph Paul, Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew, Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Hellmann, Matthew D, Hamid, Omid, Goldman, Jonathan W, Soria, Jean-Charles, Dolled-Filhart, Marisa, Rutledge, Ruth Z, Zhang, Jin, Lunceford, Jared K, Rangwala, Reshma, Lubiniecki, Gregory M, Roach, Charlotte, Emancipator, Kenneth, Gandhi, Leena
Published in The New England journal of medicine (21.05.2015)
Published in The New England journal of medicine (21.05.2015)
Get full text
Journal Article
High interobserver and intraobserver reproducibility among pathologists assessing PD‐L1 CPS across multiple indications
Nuti, Shanthy, Zhang, Yiwei, Zerrouki, Nabila, Roach, Charlotte, Bänfer, Gudrun, Kumar, George L, Manna, Edward, Diezko, Rolf, Kersch, Kristopher, Rüschoff, Josef, Jasani, Bharat
Published in Histopathology (01.12.2022)
Published in Histopathology (01.12.2022)
Get full text
Journal Article
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
Kalpakoff, Megan, Hund, Stephanie, Musser, Jeanette, Roach, Charlotte, Apostolaki, Angeliki, Vilardo, Monika, Peltz, Lindsay, Watts, Brittany, LaPlaca, Chris, Tabuena-Frolli, Siena, DiMaio, Michael A, Welcher, Rosanne, Kulangara, Karina
Published in Applied immunohistochemistry & molecular morphology (01.10.2021)
Published in Applied immunohistochemistry & molecular morphology (01.10.2021)
Get more information
Journal Article
Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma
Dolled-Filhart, Marisa, Ebbinghaus, Scot, Roach, Charlotte, Ponto, Gary, Toland, Grant, Jansson, Malinka, Emancipator, Kenneth
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx
Kulangara, Karina, Hanks, Debra Ann, Waldroup, Stephanie, Peltz, Lindsay, Shah, Supriya, Roach, Charlotte, Juco, Jonathan Wes, Emancipator, Kenneth, Stanforth, Dave
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Development of an immunohistochemistry assay for PD-L1 for using the 22C3 antibody in melanoma
Roach, Charlotte, Musser, Jeanette, Ponto, Gary, Toland, Grant, Jansson, Malinka, Emancipator, Kenneth, Dolled-Filhart, Marisa, Stanforth, Dave, Kulangara, Karina
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Dolled-Filhart, Marisa, Roach, Charlotte, Toland, Grant, Stanforth, Dave, Jansson, Malinka, Lubiniecki, Gregory M, Ponto, Gary, Emancipator, Kenneth
Published in Archives of pathology & laboratory medicine (1976) (01.11.2016)
Published in Archives of pathology & laboratory medicine (1976) (01.11.2016)
Get full text
Journal Article
Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC)
Dolled-Filhart, Marisa, Roach, Charlotte M., Toland, Grant, Musser, Jeanette, Lubiniecki, Gregory M., Ponto, Gary, Emancipator, Kenneth
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001
Garon, Edward B., Rizvi, Naiyer, Hui, Rina, Leighl, Natasha B., Balmanoukian, Ani S., Eder, Joseph P., Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew A., Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Zhang, Jin, Rangwala, Reshma A., Lubiniecki, Gregory M., Roach, Charlotte M., Emancipator, Kenneth, Gandhi, Leena
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001
Rizvi, Naiyer A., Garon, Edward B., Leighl, Natasha, Hellmann, Matthew David, Patnaik, Amita, Gandhi, Leena, Eder, Joseph Paul, Rangwala, Reshma A., Lubiniecki, Gregory, Zhang, Jin, Emancipator, Kenneth, Roach, Charlotte M., Rutledge, Ruth, Hui, Rina, Ahn, Myung-Ju, Horn, Leora, Felip, Enriqueta, Carcereny Costa, Enric
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL)
Puzanov, Igor, Dummer, Reinhard, Schachter, Jacob, Pavlick, Anna C., Gonzalez, Rene, Ascierto, Paolo Antonio, Margolin, Kim Allyson, Hamid, Omid, Agarwala, Sanjiv S., Carlino, Matteo S., Utikal, Jochen, Lotem, Michal, Ribas, Antoni, Mohr, Peter, Roach, Charlotte M., Dolled-Filhart, Marisa, Li, Xiaoyun Nicole, Ebbinghaus, Scot, Kang, Soonmo Peter, Daud, Adil
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article